Market Research Logo

Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016

Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016’, provides in depth analysis on Histone Deacetylase 1 (EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 1 (EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (EC 3.5.1.98)
  • The report reviews Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Deacetylase 1 (EC 3.5.1.98) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (EC 3.5.1.98)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (EC 3.5.1.98) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 1 (EC 3.5.1.98) Overview
Therapeutics Development
Histone Deacetylase 1 (EC 3.5.1.98) - Products under Development by Stage of Development
Histone Deacetylase 1 (EC 3.5.1.98) - Products under Development by Therapy Area
Histone Deacetylase 1 (EC 3.5.1.98) - Products under Development by Indication
Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Histone Deacetylase 1 (EC 3.5.1.98) - Products under Development by Companies
Histone Deacetylase 1 (EC 3.5.1.98) - Products under Development by Universities/Institutes
Histone Deacetylase 1 (EC 3.5.1.98) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 1 (EC 3.5.1.98) - Companies Involved in Therapeutics Development
4SC AG
Acetylon Pharmaceuticals, Inc.
Chipscreen Biosciences Ltd
Curis, Inc.
GlaxoSmithKline Plc
HitGen LTD
IRBM Science Park SpA
Italfarmaco S.p.A.
MEI Pharma, Inc.
Merck & Co., Inc.
Mirati Therapeutics Inc.
Oncolys BioPharma Inc.
Sigma-Tau S.p.A.
Syndax Pharmaceuticals, Inc.
TetraLogic Pharmaceuticals
Histone Deacetylase 1 (EC 3.5.1.98) - Drug Profiles
4SC-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-738 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACY-957 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chidamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crocetin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-3158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUDC-907 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mocetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
N-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBP-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pracinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remetinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Histone Deacetylase 1 for Beta-Thalassemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vorinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 1 (EC 3.5.1.98) - Dormant Projects
Histone Deacetylase 1 (EC 3.5.1.98) - Featured News & Press Releases
Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting
May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting
May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One
Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting
Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting
Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study
Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models
Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting
Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by 4SC AG, H1 2016
Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
Pipeline by Chipscreen Biosciences Ltd, H1 2016
Pipeline by Curis, Inc., H1 2016
Pipeline by GlaxoSmithKline Plc, H1 2016
Pipeline by HitGen LTD, H1 2016
Pipeline by IRBM Science Park SpA, H1 2016
Pipeline by Italfarmaco S.p.A., H1 2016
Pipeline by MEI Pharma, Inc., H1 2016
Pipeline by Merck & Co., Inc., H1 2016
Pipeline by Mirati Therapeutics Inc., H1 2016
Pipeline by Oncolys BioPharma Inc., H1 2016
Pipeline by Sigma-Tau S.p.A., H1 2016
Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
Pipeline by TetraLogic Pharmaceuticals, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Dormant Projects (Contd..3), H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report